Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open-label Phase II Trial to Compare Prophylaxis of Graft Versus Host Disease With Tacrolimus and Mycophenolate Mofetil Versus Ruxolitinib After Post-transplant Cyclophosphamide

NCT04669210 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.

NCT NCT04669210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open-label Phase II Trial to Compare Prophylaxis of Graft Versus Host Disease With Tacrolimus and Mycophenolate Mofetil Versus Ruxolitinib After Post-transplant Cyclophosphamide
Lead sponsor
St. Petersburg State Pavlov Medical University
Phase
Phase 2
Overall status
Completed
Start date
November 3, 2020
Completion date
March 28, 2025
Enrollment
128 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myeloid leukemia, graft-versus-host-disease, stem cell transplant complications